Drug intelligence / Profile preview

SHDPS-4II

Development stage: Preclinical

Overview

SHDPS-4II is a sulfated derivative of an α-D-glucan (HDPS-4II) that functions as a selective blocker of aldolase A (ALDOA). ALDOA is known to promote hepatocellular carcinoma (HCC) growth, making it a potential therapeutic target. SHDPS-4II has demonstrated high affinity for ALDOA and has been shown to markedly inhibit the proliferation of HCC cells both in vitro and in vivo by blocking ALDOA. Its sulfated modification enhances its affinity and anti-HCC effects compared to the original α-D-glucan.

Other names: 3-O-sulfated HDPS-4II

Targets

ALDO (Fructose-bisphosphate aldolase A)

Beyond the preview

Go deeper on SHDPS-4II.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHDPS-4II.

Explore the full profile